NOVEL STRATEGIES FOR PLANT-DERIVED ANTICANCER AGENTS

被引:21
作者
KINGHORN, AD
FARNSWORTH, NR
BEECHER, CWW
SOEJARTO, DD
CORDELL, GA
PEZZUTO, JM
WALL, ME
WANI, MC
BROWN, DM
ONEILL, MJ
LEWIS, JA
BESTERMAN, JM
机构
[1] UNIV ILLINOIS, COLL PHARM, DEPT MED CHEM & PHARMACOGNOSY, PROGRAM COLLABORAT RES PHARMACEUT SCI, CHICAGO, IL 60612 USA
[2] RES TRIANGLE INST, DIV CHEM & LIFE SCI, RES TRIANGLE PK, NC 27709 USA
[3] GLAXO WELLCOME MED RES CTR, STEVENAGE SG1 2NY, HERTS, ENGLAND
[4] GLAXO WELLCOME INC, DEPT CELL BIOL, RES TRIANGLE PK, NC 27709 USA
来源
INTERNATIONAL JOURNAL OF PHARMACOGNOSY | 1995年 / 33卷
基金
美国国家卫生研究院;
关键词
DRUG DISCOVERY; ANTICANCER AGENTS; HIGHER PLANTS; NAPRALERT DATABASE; ACTIVITY-GUIDED ISOLATION;
D O I
10.3109/13880209509067087
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
In this collaborative project oriented towards the discovery of novel anticancer agents from higher plants, a coordinated research effort is now well-established at the various consortial sites. Over 2,300 authenticated plant samples, mostly endemic to tropical countries, have been collected by experienced resident botanists, with the NAPRALERT database having been used to pre-select some of these through the weighting of published experimental data. To date, over 3,000 plant extracts have been prepared and evaluated in a broad range of cell- and mechanism-based bioassays that were selected because of their relevance to the proliferation of cancerous cells. Prioritization of plant extracts Sor activity-guided fractionation is conducted through a team approach at group meetings, and dereplication procedures for interfering plant polyphenols have been developed. A large number of active compounds have been obtained many of novel structure, and the status of a selection of these (compounds 1-17) as candidates for pre-clinical development is described in this review.
引用
收藏
页码:48 / 58
页数:11
相关论文
共 61 条
  • [1] ALLEY MC, 1988, CANCER RES, V48, P589
  • [2] [Anonymous], 1990, ALKALOIDS CHEM PHARM, DOI DOI 10.1016/S0099-9598(08)60097-8
  • [3] Ayres D.C, 1990, LIGNANS CHEM BBIOLOG
  • [4] CANCER STATISTICS, 1994
    BORING, CC
    SQUIRES, TS
    TONG, T
    MONTGOMERY, S
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 1994, 44 (01) : 7 - 26
  • [5] BOYD MR, 1992, DEV ONCOL, V68, P11
  • [6] CAN ETHNOPHARMACOLOGY CONTRIBUTE TO THE DEVELOPMENT OF NEW ANTICANCER DRUGS
    CORDELL, GA
    BEECHER, CWW
    PEZZUTO, JM
    [J]. JOURNAL OF ETHNOPHARMACOLOGY, 1991, 32 (1-3) : 117 - 133
  • [7] CORDELL GA, 1993, S SERIES, V534, P193
  • [8] CRAGG GM, 1993, ACS SYM SER, V534, P80
  • [9] THE TAXOL SUPPLY CRISIS - NEW NCI POLICIES FOR HANDLING THE LARGE-SCALE PRODUCTION OF NOVEL NATURAL PRODUCT ANTICANCER AND ANTI-HIV AGENTS
    CRAGG, GM
    SCHEPARTZ, SA
    SUFFNESS, M
    GREVER, MR
    [J]. JOURNAL OF NATURAL PRODUCTS, 1993, 56 (10): : 1657 - 1668
  • [10] DNA TOPOISOMERASE-1 AND TOPOISOMERASE-2 AS TARGETS FOR RATIONAL DESIGN OF NEW ANTICANCER DRUGS
    CUMMINGS, J
    SMYTH, JF
    [J]. ANNALS OF ONCOLOGY, 1993, 4 (07) : 533 - 543